CRISPR Therapeutics (CRSP) Proxy filing summary

Executive summary

• The annual general meeting is scheduled for June 4, 2026, with shareholders voting on key proposals including financial statements, board elections, compensation, capital structure, and incentive plans.

• Shareholders will vote on the approval of the Swiss management report, consolidated and statutory financial statements for 2025, and the appropriation of a net loss of CHF 508.7 million to be carried forward.

• Discharge of board and executive committee members from liability for 2025 activities is proposed.

• Eleven directors, including the chairman, are nominated for re-election for one-year terms, and four members are nominated for re-election to the Compensation Committee.

• Proposals include increases to the capital band and conditional share capital, approval of a new stock option and incentive plan, and re-election of auditors and the independent voting rights representative.

Voting matters and shareholder proposals

• Shareholders will vote on 13 proposals, including approval of financial statements, board and committee elections, compensation, capital increases, and incentive plans.

• Board recommends voting "FOR" all proposals, including compensation limits, capital structure changes, and the new 2026 Stock Option and Incentive Plan.

• Shareholders can submit proposals for future meetings if they meet ownership thresholds and deadlines.

Board of directors and corporate governance

• The board consists of eleven directors, all standing for re-election, with a mix of industry, financial, and scientific expertise.

• The chairman and CEO roles are combined, with a lead independent director designated for oversight.

• All board committees (Audit, Compensation, Nominating) are composed of independent directors.

• The board emphasizes diversity of skills and backgrounds, though no formal diversity policy is in place.